- Latest available (Revised)
- Point in Time (01/04/2010)
- Original (As made)
Version Superseded: 01/04/2012
Point in time view as at 01/04/2010.
There are currently no known outstanding effects for the The Medicines (Products for Human Use) (Fees) Regulations 2010 (revoked),
PART 5
.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
18.—(1) Unless regulation 52 (revocations and savings) applies, the fee for an application—
(a)under regulation 4 (applications for the grant, renewal or variation of a United Kingdom marketing authorization) of the Marketing Authorisation Regulations M1 for the variation of a United Kingdom marketing authorization;
(b)under regulation 6 (consideration and grant or refusal, of an application for, or for renewal or variation of, a traditional herbal registration) of the Herbal Regulations for the variation of a traditional herbal registration;
(c)under section 30 (variation of licence on application of holder) of the Act M2 for the variation of a product licence, a manufacturer's licence or a wholesale dealer's licence; or
(d)under regulation 44 (variation of manufacturing authorisation) of the Clinical Trials Regulations M3 for the variation of a manufacturing authorisation,
is the fee mentioned in paragraph (2).
(2) The fee referred to in paragraph (1) is—
(a)the fee prescribed in Part 4 of Schedule 1 in connection with the application; and
(b)in respect of an inspection of a site made in connection with the application, the fee payable in accordance with regulations 27 to 29 and 31.
(3) Unless regulation 28 applies, the fee in paragraph (1) is payable by the applicant.
Marginal Citations
M1Amendments to regulation 4 have been made by S.I. 2001/795, 2002/236, 2005/2759 and 2006/1952.
M2Section 30 was substituted by S.I. 2005/2789.
M3Amendments to regulation 44 have been made by S.I. 2006/1928.
19.—(1) A person who sends a valid notice of amendment under regulation 24 (amendments by the sponsor) of the Clinical Trial Regulations M4 relating to amendment of the dossier accompanying a request for authorisation in accordance with paragraph 11 of Part 2 of Schedule 3 (request for authorisation) to those Regulations must pay the fees mentioned in paragraph (2).
(2) The fees referred to in paragraph (1) are—
(a)the fee prescribed in paragraph 44 of Part 4 of Schedule 1 in connection with that amendment; and
(b)in respect of an inspection of a site made in connection with the application, the fee payable in accordance with regulations 27 to 29 and 31.
Marginal Citations
M4Amendments to regulation 24 have been made by S.I. 2006/1928.
20.—(1) Unless paragraph (3) or (5) applies, a separate fee is payable in respect of each application to vary each term of a marketing authorization.
(2) Unless paragraph (5) applies, a separate fee is payable in respect of each variation of each provision of a traditional herbal registration, manufacturing authorisation or licence applied for in any one application.
(3) A separate fee is not payable for each application to vary a term of a marketing authorization which—
(a)falls within the same type of group application; or
(b)the licensing authority—
(i)in consultation with other Member States concerned, have agreed, in accordance with Article 7(2)(b) of EC Regulation No. 1234/2008, should be subject to the procedure for grouping of variations within the meaning of that Article; and
(ii)have agreed fall, or should be treated as falling, within the same type of group application.
(4) For the purposes of paragraph (3) the reference to a group application means an application which is a—
(a)Minor Variation (Type IB) Group Application;
(b)Major Variation (Type II) Group Application;
(c)Major Variation (Type II) Complex Group Application; or
(d)Major Variation (Type II) Extended Complex Group Application.
(5) A separate fee is not payable for a variation which is wholly consequential upon another variation of a provision of a marketing authorization, traditional herbal registration, manufacturing authorisation or licence which is applied for in the same application.
(6) In a case where a recommendation on the classification of a variation is made in accordance with Article 5 of EC Regulation No. 1234/2008, the fee payable for the application made in respect of that variation shall be the appropriate fee for the classification given to the variation or, as the case may be, the appropriate fee which arises as a consequence of the classification given to the variation.
(7) In this regulation and Part 4 of Schedule 1—
“Major Variation (Type II) Group Application” means an application for several variations to one marketing authorization and—
at least one of the variations is a major variation of type II;
subject to sub-paragraph (c), the variations fall within the scope of Article 7(2)(b) of EC Regulation No. 1234/2008;
the variations do not include a variation—
of a kind referred to in paragraph 1 (extension of the marketing authorisation) or paragraph 3 (minor variation of type IB and consequential variations) of Annex III to EC Regulation No. 1234/2008;
which relates to a change which is referred to in paragraph 23 of Schedule 1 (Type II Complex Variation Application); or
of a marketing authorization so that the medicinal product is indicated for a use referred to in paragraph 9(a) or (b) of Schedule 1 (Extended Type II Complex Variation Application); and
the variations may include one or more minor variations of type IA or one or more minor variations of type IB;
“Major Variation (Type II) Complex Group Application” means an application for several variations to one marketing authorization and—
at least one of the variations relates to one or more of the changes referred to in paragraph 23 of Schedule 1 (Type II Complex Variation Application);
subject to sub-paragraph (c), the variations fall within the scope of Article 7(2)(b) of EC Regulation No. 1234/2008;
the variations do not include a variation of—
a kind referred to in paragraph 1 or paragraph 3 of Annex III to EC Regulation No. 1234/2008; or
a marketing authorization so that the medicinal product is indicated for a use referred to in paragraph 9(a) or (b) of Schedule 1; and
the variations may include one or more minor variations of type IA or one or more minor variations of type IB or one or more major variations of type II;
“Major Variation (Type II) Extended Complex Group Application” means an application for several variations to one marketing authorization and—
at least one of the variations is a variation to a marketing authorization so that the medicinal product is indicated for a use referred to in paragraph 9(a) or (b) of Schedule 1;
subject to sub-paragraph (c), the variations fall within the scope of Article 7(2)(b) of EC Regulation No. 1234/2008;
the variations do not include a variation of a kind referred to in paragraph 1 of Annex III to EC Regulation No. 1234/2008; and
the variations may include minor variations of type IA, minor variations of type IB or other major variations of type II or a variation relating to a change referred to in paragraph 23(a), (b) or (c) of Schedule 1;
“major variation of type II” has the meaning given in Article 2(3) of EC Regulation No. 1234/2008;
“Minor Variation (Type IB) Group Application” means an application for several variations to one marketing authorization and—
at least one of the variations is a minor variation of type IB;
subject to sub-paragraph (c), the variations fall within the scope of Article 7(2)(b) of EC Regulation No. 1234/2008;
the variations do not include—
a variation of a kind referred to in paragraph 1 or paragraph 2 of Annex III of EC Regulation No. 1234/2008; or
a major variation of type II; and
the variations may include one or more minor variations of type IA;
“minor variation of type 1A” has the meaning given in Article 2(2) of EC Regulation No. 1234/2008;
“minor variation of type 1B” has the meaning given in Article 2(5) of EC Regulation No. 1234/2008; and
“work sharing” means the worksharing procedure within the meaning of Article 20 of EC Regulation No. 1234/2008.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: